In-frame deletions in exon 19 are the most frequently reported EGFR mutations in lung cancer patients present at a rate of around 46.3% to 76.2%, followed by L858R missense mutation in exon 21 present at a rate of 26% to 38% as reported by Noronha et. This evidence concerns the gene EGFR and lung cancer.